Company TMS Co., Ltd.

Equities

4891

JP3544960002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 06:30:00 12/12/2024 GMT			5-day change	1st Jan Change
213.00 ^JPY	-2.29%		-1.39%	+13.30%

11-08	TMS Co., Ltd. Announces Publication of the Phase 2a Clinical Trial Results of JX10 (TMS-007) in the American Heart Association and American Stroke Association?s Stroke	CI
10-02	Yojee Limited Successfully Completes Deployment of Its TMS At A Further Two Sites for PT APP Purinusa Ekapersada	CI

Business description: TMS Co., Ltd.

TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.

Number of employees: 14

Managers: TMS Co., Ltd.

Director	Title	Age	Since
Takuro Wakabayashi PSD	President	57	30/04/2018
Noriaki Inamura CTO	Chief Tech/Sci/R&D Officer	69	30/11/2020
Go Ito ADM	Chief Administrative Officer	54	31/01/2018
Kazuo Honda CTO	Chief Tech/Sci/R&D Officer	75	31/03/2015

See TMS CO., LTD. governance

Members of the board: TMS Co., Ltd.

Manager	Title	Age	Since
Keiji Hasumi CHM	Chairman	67	30/06/2021
Takuro Wakabayashi BRD	Director/Board Member	57	30/04/2011
Go Ito BRD	Director/Board Member	54	30/04/2018
Noriaki Inamura BRD	Director/Board Member	69	30/11/2020
Ken Takanashi BRD	Director/Board Member	60	29/02/2020
Reiko Namikawa BRD	Director/Board Member	71	30/04/2021

Composition of the Board of Directors

Shareholders: TMS Co., Ltd.

Name	Equities	%	Valuation
DCI Partners KK 10.19 %	4,107,920	10.19 %	6 M ¥
RTW Investments LP 8.948 %	3,608,716	8.948 %	5 M ¥
TOHOKU University Venture Partners Co., Ltd. 7.057 %	2,845,960	7.057 %	4 M ¥
Nissay Capital Co., Ltd. 6.105 %	2,462,340	6.105 %	4 M ¥
Mitsubishi UFJ Capital Co., Ltd. 5.802 %	2,339,920	5.802 %	3 M ¥

List of TMS CO., LTD. shareholders

Company details: TMS Co., Ltd.

TMS Co., Ltd.

Keio Fuchu 1-chome Building, 11/F 1-9 Fuchu-cho

183-0055, Tokyo

http://www.tms-japan.co.jp/ja/index.html

Other Biotechnology & Medical Research

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
TMS CO., LTD.	-2.29%	-1.39%	+3.40%	-	57.66M
LONZA GROUP AG	+6.20%	+6.54%	+69.32%	-25.36%	42.67B
IQVIA HOLDINGS INC.	-1.05%	-1.03%	-7.05%	-25.62%	36.49B
CELLTRION, INC.	+1.15%	+0.66%	+3.66%	-6.06%	26.56B
ICON PUBLIC LIMITED COMPANY	-1.75%	-1.08%	-22.76%	-23.43%	17.52B
MODERNA, INC.	+3.25%	+2.95%	-47.73%	-83.33%	16.49B
UNITED THERAPEUTICS CORPORATION	-0.02%	-3.27%	+47.90%	+92.06%	16.17B
BIO-TECHNE CORPORATION	-0.40%	+1.21%	+11.32%	-34.07%	12.2B
MEDPACE HOLDINGS, INC.	-0.13%	-1.39%	+21.16%	+66.86%	10.59B
QIAGEN N.V.	+0.20%	+5.46%	+6.41%	-17.62%	10.26B
Average	+0.21%	+0.68%	+8.56%	-6.28%	18.9B
Weighted average by Cap.	+1.19%	-0.03%	+14.89%	-12.50%